Dr. Agarwal’s Health Care Limited - IPO

Incorporated in 2010, Dr. Agarwal's Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.

As of September 30, 2024, there were 737 doctors providing care to patients across the company's facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries.

The Services provided by the company are:-

Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments;

Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).

Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium.

As of September 30, 2024, the company's Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities).

As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities.

Competitive Strength

• Largest eye care services provider in India with a trusted brand
• End-to-end, comprehensive eye care services offering
• Scalable, asset-light, hub-and-spoke operating model
• Proven clinical excellence is driven by a strong clinical board and a history of surgical innovations. 
• Doctor-promoters leading a team of qualified medical professionals and supported by experienced management
• Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability

1. Largest eyecare services provider in India with a trusted brand.

2. End-to-end, comprehensive eyecare services offering.

3. Scalable, asset-light, hub-and-spoke operating model.

4. Proven clinical excellence driven by a strong clinical board and history of surgical innovations.

5. Doctor-promoters leading a team of qualified medical professionals and supported by an experienced management.

6. Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability.

1. The company engage doctors through retainership arrangements and there is no assurance that its doctors will not prematurely terminate their arrangements with it. If the company is not able to attract and retain its doctors and other medical professionals, the company business, financial condition, results of operations and cash flows may be adversely affected.

2. The company business depends on the strength of the company brand equity and reputation. Failures to maintain and enhance its brand equity and reputation, including due to negative publicity, may adversely affect its business, reputation, financial condition, results of operations and prospects.

3. The company operates in a regulated industry, and its failures to comply with applicable safety, health, environmental, labor and other regulations, or to obtain or renew approvals, may adversely affect its business, reputation, financial condition, results of operations and cash flows.

4. A significant majority of its Facilities are located in the states of Tamil Nadu (in particular, Chennai), Maharashtra and Karnataka in India and any adverse developments in relation to these Facilities could adversely affect its business, financial condition, results of operations and cash flows.

5. The company is exposed to legal claims and regulatory actions arising from the provision of healthcare services and may be subject to liabilities arising from claims of malpractice and medical negligence which could adversely affect its business, financial condition, results of operations, cash flows, reputation and prospects.

6. Its international operations expose it to management, legal, tax, political and economic risks, and its failure to address such risks could adversely affect the company business, results of operations, financial condition and cash flows.

7. Its hub-and-spoke model may not be successful and the company may not be able to expand into new geographic regions, which could adversely affect its business, financial condition and results of operations.

8. The company has pursued and will likely continue to pursue strategic acquisitions for inorganic growth. Its inability to successfully identify, acquire and integrate suitable opportunities on commercially reasonable terms in the future could adversely affect its business, financial condition, cash flows and results of operations.

9. Its historical performance is not indicative of the company future growth or financial results and if its fail to manage the company growth or implement its growth strategies, the company business, financial condition and results of operations may be adversely affected.

10. The company is exposed to credit risks in respect of payments from third parties including under central and state government schemes, government corporations, insurance companies and third party administrators. If the company does not receive payments on a timely basis, its business, financial condition, results of operations, cash flows and prospects may be adversely affected.